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Habiba A. Thawer, PT, MSc; 1 Pamela E. Houghton, PT, PhD; 2
Luther C. Kloth, PT, MS, CWCS;3 Anna Butryn, B5c4
From the 'PhD Program in Rehabilitation Sciences; 
1School of Physical Therapy, Faculty of Health Sciences, University of
Western Ontario, London, Ontario, Canada; 'Department of Physical Therapy, Marqueffe University, Milwaukee, 
Wisconsin; 'Department of Physiology, Faculty of Medicine, University of Western Ontario, London, Ontario, Canada 
Abstract: The purpose of the present study was to examine the effect of electrical stimulation (ES) on 
the closure of full-thickness excisional wounds in mice with type-1 experimental diabetes mellitus (DM). 
Alloxon monohydrate (1 OOmg/kg) was used to induce experimental OM in mole CD-1 mice (n = 88). Ful� 
thickness skin excisions (lcm2) in diabetic (urine glucose > 0) and no�iobetic (urine glucose = 0) mice 
were administered 1, 3, or 5 treatments of ES (200µs, 200 Hz) for 15 minutes, at O (sham), 5, 10, or 
12.5 volts. Alloxon injection resulted in a positive urine glucose test in 48 mice yielding on induction rote 
for OM of 54.5 percent. All groups exhibited decreases in wound length, perimeter, and surface area 
between days 2 and 16 following the creation of wounds. Non<liabetic wounds treated with ES hod the 
greatest percentage (60%) of closure. Diabetic wounds treated with ES hod a greater percentage of clo­
sure (36%) compared with sham-treated diabetic animals (12.5%). Treatment of wounds with the highest 
voltage of ES (12.5V) produced significant (P < 0.01) decreases in the surface area, and significant (P < 
0.01) changes in the shapes of wounds in both diabetic and non-diabetic animals compared with sham­
treated animals. These results support the clinical use of this adjunctive therapy to accelerate the closure of 
ulcers due to OM. 
This study was funded by the VP Research Grant from the University of Western Ontario and with funds from the Ontario 
Graduate Student Scholarship and the Physiotherapy Foundation of Canada by an Ann Collins Whitmore Memorial Award. 
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T he World Health Organization estimates the total number of people with diabetes 
mellitus (OM) in the population will dou­
ble to 239 million by the year 2010. OM is a cluonic 
disease characterized by atherosclerosis, neuropa­
thy, and an increased incidence of infection. These 
sequelae of the disease process, compounded by the 
metabolic problems related to hyperglycemia, 
insulin deficiency, and/ or insulin resistance con­
tribute to impaired healing in individuals with OM. 
Foot ulceration and infection are leading causes of 
hospitalization among individuals with OM.' 
Approximately 15 percent of all individuals with 
OM will develop foot or leg ulceration at some time 
during their lives contributing to one-half to two­
thirds of all non-traumatic amputations in the Unit­
ed States.u 
Numerous clinical reports including at least nine 
randomized controlled clinical trials have docu­
mented that ES accelerates wound closure in chron­
ic wounds including diabetic ulcers .... ' Previous 
research studies have examined electrically-stimu-
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Figure 1. Bars represent the mean :± the standard 
deviation of the mean (SEMJ of the surfac e a rea, 
perimeter, length, and shape factor of wounds determined 
using computer image analysis. Measurements of wound 
dimensions were made from wounds placed in non­
diabetic (NJ and diabetic (DJ animals th'at had been 
treated with electrical stimulation (ES} at an intensity of OV, 
5V, 1 OV, or 12.SV for 15 minutes on alternate days for a 
16-day period. A single asterisk (*} indicates significant 
differences between diabetic and non-diabetic animals 
treated with 12.SV of ES compared with sham-treated 
diabetic and non-diabetic animals. Double asterisks (* *} 
indicate significant differences between non-diabetic 
animals treated with 1 OV of ES and sham-treated non­
diabetic animals. The number of animals (n} in each 
group is indicated at the bottom of the figure. 
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lated wound closure in healthy animal models 
using acute wounds.s-12 However, one study exam­
ined the effect of ES in diabetic mice using a full­
thickness incisional model.0 Alloxan monohydrate, 
a drug know to induce diabetes by destruction of 
pancreatic islet beta cells by five days following 
intravenous injection,14 was used to induce diabetes 
in these animals. Diabetic mice were treated with 
sham or ES daily for 15 minutes, with the negative 
electrode placed proximal to the wound. The study 
demonstrated diabetic animals treated with ES had 
greater tensile wound strength compared to sham­
treated control animals. 0 Moreover, administration 
of ES to the wounds of diabetic animals resulted in 
an almost complete return of the wound histology 
to normal tissue appearance. 
No studies to date have examined the effect of ES 
on the closure of full-thickness excisional wounds in 
diabetic mice. The purpose of this study was to 
identify a stimulus intensity of ES that produced the 
greatest healing of full-thickness excisional wounds 
in animals with DM. This optimal stimulus intensi­
ty of ES was then used in a second sh.ldy to examine 
the effect of ES on the rate of healing of wounds in 
diabetic mice over time. 
Materials and Methods 
Animals. Eighty-eight adult male CD-1 mice 
(Charles River Laboratories, St. Constant, QC, 
Canada) weighing between 22 and 28g were used 
for this study. Upon arrival, individual animals 
were identified with ear tags, placed into groups, 
and housed in an animal care facility approved 
by the Canadian Council on Animal Care, with 
controlled temperature (22°C) and light (12 hour 
light/ 12 hour dark cycle). Food and water were 
provided ad libitum.
Diabetes Induction 
Following five days of acclimatization, all ani­
mals were anesthetized with an intraperitoneal 
injection of ketamine/Xylazine (.03ml/10g of 
body weight), and given an intravenous injection 
of all ox an monohydrate (100mg / kg of body 
weight) via the tail vein. This agent has been used 
extensively to induce OM in experimental ani­
mals, 15 and is k nown to selectively destroy 
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Figure 2. Full-thickness excisional wounds were created dorsally in all animals. Wounds in diabetic animals 
treated with the highest voltage of ES (12.5V) appeared circular in shape (A) compared with sham-treated 
wounds in diabetic animals (8) which appeared more linear in shape by day 16. 
insulin-producing pancreatic islet �-cells within 
seven days of intravenous administration.13•15-21 
This selective vulnerability of the islet �-cells 
compared with other cell types has been attrib­
uted to the rapid accumulation of the drug in the 
�-cells22 and the high sensitivity of the �-cells
toward peroxidases resulting from the metabo­
lism of alloxan relative to other tissues.23-26 
The presence of diabetes was confirmed using 
urine glucose test sticks (Chemstrip; Boehringer 
Mannhein, Canada) at five days post-alloxan 
injection and was repeated at the time of sacrifice. 
Body weights were also recorded using an elec­
tronic balance accurate to 1.0mg (ER- 60A; Johns 
Scientific Inc. ,  Canada) at the time of alloxan 
injection and prior to sacrifice. Animals that 
demonstrated symptoms typical of the experi­
mental diabetic state such as glucosuria, polyuria, 
weight loss, and polydipsia were termed diabetic. 
A value greater than zero of the amount of glu­
cose in the urine indicated the presence of OM. 
Animals that failed to demonstrate any level of 
glucose in the urine and that failed to demon­
strate polyuria, weight loss, and polydipsia were 
termed non-diabetic. 
Surgery and Recovery 
On the seventh day following alloxan monohy­
drate injection, the area between the shoulder 
Vol. 12, No. 6 November/December 2000 
blades was shaved, washed with surgical scrub, 
and swabbed with alcohol and Betadine. Using a 
template to ensure reproducibility and consisten­
cy, a square-shaped lcm2 full-thickness excisional 
wound was placed in each animal between the 
shoulder blades under general anesthesia (keta­
mine / X y lazine; 0.03ml/10g of body weight) 
using sterile surgical techniques. Although indi­
viduals with OM are typically inflicted with 
wounds on the feet, it was necessary to produce 
wounds dorsally between the shoulder blades to 
minimize tampering of the wound by the ani­
mals. Since wound-dressing materials are not 
well tolerated by these animals, all wounds were 
left open for the duration of the study. However, 
the conducting gel that was used was retained on 
all wound sites following treatments in order to 
create a similar moist wound-healing environ­
ment. As a result, most animals developed a thin 
eschar over the wound site until complete epithe­
lialization occurred. 
Treatment 
Animals were then randomly assigned to receive 
either true ES or sham treatment. A Portmax 300 
electrical stimulation device (Medelco Ltd., Missis­
sauga, ON, Canada) was used to administer a 
monophasic, pulsed current with a pulse duration 
of 200 µseconds, delivered at a frequency of 200 
161 
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Figure 3. Bars represent the mean :t SEM of wound 
surface area measured on day following surgery and 
prior to the onset of treatments (D 1 ), and following 2 
(D2), 8 (DB), and 16 days post surgery. Measurements 
are presented for non-diabetic animals that received 
either an electrical stimulus at an intensity of 12.5V 
(NES) or sham treatment (NS), and diabetic animals 
following administration of ES (12.5V) (DES) or sham 
treatment (OS). 
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Figure 4. Bars represent the percentage of the total 
wounds in each treatment group that had closed at the 
time of sacrifice (day 16 post surgery). Measurements 
are presented for non-diabetic animals that either 
received an electrical stimulus at an intensity of 12.5V 
(ES) or sham treatment  (SJ and diabetic animals 
following a 12.5V electrical stimulus (ES) or sham 
treatment (SJ. 
pulses per second. Throughout the study, negative 
polarity was maintained at the treatment electrode 
(cathode}, which was  placed directly over the 
wound site. Treatments were initiated 24 hours fol­
lowing the infliction of wounds. To verify the volt­
age delivered, the electrical stimulator was calibrat­
ed at each treatment voltage using an oscilloscope 
(HM 408, HAMEG GmbH, 0-6000 Frankfurt am 
Main 71, West Germany). Immediately prior to 
tre atment, animals were placed in individual 
restraining devices in the form of narrow cones fab-
162 
ricated of a flexible f
i
berglass mesh. Consistent elec­
trode attachment was maintained during the 15-
minute treatment sessions. Sterile conducting gel 
(DuoDerm; ConvaTec, Princeton, NJ) was applied 
to cover the wound site, directly over which the 
2cm2 trea tment electrode (cathode) was then 
secured. The size of the treatment electrode was 
greater than that of the wound to ensure complete 
coverage of the wound. A larger non-treatment 
electrode (anode; 4cm2) was wrapped around each 
animal's tail to complete the circuit. Electrodes were 
cut out of Metaline gauze (Bohmann GmbH & Co., 
KG, Germany) and were moistened in sterile saline 
solution prior to application. Sham-treated non-dia­
betic and diabetic mice were treated identically, but 
the electrical stimulator was not activated. All pro­
cedures were in accordance with guidelines of the 
Canadian Council for Animal Care and were 
approved by the Animal Care Committee at the 
University of Western Ontario. 
Study Design 
In th.e first study, animals ( diabetic [n = 15] and 
non-diabetic [n = 18]) received either ES at one of 
the following intensities (5.0, 10.0, 12.5V) or sham 
treatment. After the first electrical treatment, it was 
apparent that some animals were not tolerating the 
higher intensities of electrical current (20V and 
40V). Data derived from these animals were elimi­
nated from the study. The remaining animals that 
were originally allocated to the 20V and 40V groups 
were combined with animals in the 12.SV group for 
the remaining treatments and for subsequent data 
analysis. At the end of the 16-day treatment period, 
wound size was measured using planimetric 
(PLANIX 7; Digital Planimeter; Koizumi Sokki Mfg. 
Co. Ltd., Nagaoka-Shi, Japan) and computerized 
image analysis (Northern Exposure; Empix Imag­
ing, Mississauga, ON, Canada) techniques. 
The second study was designed to examine the 
time course of the changes that occurred in wounds 
treated with electrical stimulation. To do so, 
wounded animals (diabetic [n = 33] and non-diabet­
ic [n = 22]) received treatments of either electrical 
current at the optimal intensity determined during 
the first stage of this study (12.SV), or sham treat­
ment. The animals were randomly divided into two 
groups, and each group was treated on alternate 
Continued on poge 164 
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Apligraf is also indicated for use with standard diabetic 
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pathic diabetic foot ulcers of greater than 3 weeks' dura­
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tinue product use if a patient shows evidence of an 
immunological reaction. Patients should notify their 
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Table 1. Urine glucose (% • g/dll and weight (g) on the day of surgery 
and at sacrifice of non-diabetic (NS) and diabetic (OS) animals that 
received sham treatment, and non-diabetic (NES) and diabetic (DES) 
animals that were treated with ES 
using computer image analysis 
of the wound per imeter trac­
ings. This computer image 
analysis per forms measure­
ments on a digi t ized image 
obtained by a CCD camera, 
thus permitting rapid quantifi­
cation of multiple morphomet­
ric features of the wound. The 
digitized image is then trans­
formed into a binary image 
using a process called mono­
chrome or grey-level threshold­
ing, which permits automatic 
detection of the boundary of 
the image by a boundary trac­
ing .27 The sur face area of the 
image is then calculated using 
the pi xel counting method, 
which sums the pixels enclosed 
Surgery Sacrifice Surgery Sacrifice 
Urine Glucose(%• g/dl) Body Weight (%) 
Group N Mean:tSEM Mean:tSEM Mean:tSEM Mean:tSEM 
NS 18 O:tO O:tO 29.30:t0.86 30.91:t0.56 
NES 22 O:tO O:tO 29.00:t0.68 29.89:t0.56 
DS 19 *3.82:t0.43 3.52:t0.31 28.54:t0.61 **27.69:t0.90 
DES 29 *3.34:t0.34 3.18:t0.26 28.58:t0.62 **27.81 :t0.64 
N refers to the number of animals that were actually sacrificed. 
*NS and NES significantly IP< 0.01) different From both OS and DES.
**NS significantly (P < 0.01) different From both DS and DES. 
days. This treatment schedule was chosen to facili­
tate handling of the large nwnber of animals in the 
present study. All treatments were administered 
for 15 minutes over a period of either 2, 8, or 16 
days following the creation of wounds. At each of 
these time points (2, 8, 16 days), animals were ran­
domly selected to be sacrificed and wound size was 
determined using computer image analysis. 
Documentation of Wound Size 
All animals were sacrificed using the introduc­
tion of carbon dioxide into a Plexiglas chamber. 
Each animal's body weight and urine glucose 
was reassessed at this time (Table 1). Following 
the removal of eschar, the perimeter of each 
wound was traced onto a transparent acetate 
film. Wound tracings were repeated three times 
for each animal. Wounds were also pho­
tographed using a WILD Lietz stereomicroscope 
at 6.SX (Leica, Germany), and digitized on a 930 
D.C. RGB Sony video camera. An investigator
that remained blinded to the treatment groups
performed all documentation. 
Determination of Wound Size 
The surface area, perimeter, shape factor, 
and length of each wound were determined 
164 
by and including the image boundary, multi­
plied by the calibrated area of each pixel.27 
Other morphometric values, such as the 
perimeter and shape factor, are derived using 
standard algorithms.27 The shape factor for a 
perfect circle is 1.0. As the shape of the object 
moves toward a line, the value of the shape 
factor approaches zero. 
Validation of Wound Size Measurements 
All measurements of wound surface area, 
perimeter, and length in this study were obtained 
using an internal scale calibrated to a ruler of 
known length (1mm) under each magnification 
and had a resolution of one micron. To ensure 
accuracy of this new method of wound size 
detection using computer image analysis, the 
surface area of 10 wounds of known size was 
determined on two different occasions and com­
pared against measurements obtained using 
planimetry. The planimetry method has previ­
ously been shown to have an intrarater and inter­
rater reliability of 0.99.28-JO 
To assess the intrarater reliability of each mea­
sure of wound size using the planimetry and com­
puter image analysis methods, the intraclass correla­
tion coefficient (ICCc,.,1) was determined. The agree­
ment of the measurements from each method was 
WOUNDS: A Compendium of Clinical Research and Practice 
evaluated using an IC<=tz1>· A one-way repeated mea­
sures ANOV A was used to obtain the variance com­
ponents for calculating both the ICCs.30 
Data Analysis 
This was a stratified, block-randomized, place­
bo-controlled study, comparing the effects of OM 
and ES on the wound size of full-thickness exci­
sional cutaneous wounds in animals termed dia­
betic (urine glucose > 0) and non-diabetic (urine 
glucose = 0). The following dependent variables 
were assessed in the first stage of the study using 
a one-way analysis of variance (ANOVA) test (ex= 
0.01): surface area, perimeter, length, and shape 
factor of wounds. The data was assessed for evi­
dence of a dose dependent relationship between 
the voltage of ES delivered and the size of 
wounds. To assess for an effect of ES on the size 
of wounds over time, data from both studies was 
combined into t he following exp e r i m ental 
groups: non-diabetic (NS) and diabetic (DS) ani­
mals administered sham ES, and non-diabetic 
(NES) and diabetic (DES) animals administered 
true ES. The percent of wounds that closed by the 
end of the experimental period (day 16) in each 
group were calculated by dividing the actual 
number of wounds that closed in a group by the 
total number of wounds in that group. The sur­
face area of wounds in each treatment group (NS, 
NES, DS, DES) on each day of sacrifice ( day 2, 8, 
16) was assessed using a one-way ANOV A test
(ex= 0.01). The Tukey HSD method of multiple
comparisons was used to compare group means
(ex=.05). To further assess the effects of ES on
wound closure, all wounds ( diabetic and non-dia­
be tic) were separated into two group s: those
administered sham or true ES. A two-tailed t-test
for independent samples was then used to identi­
fy significant differences (ex= 0.01) in surface area
between sham and ES-treated groups. Dif
f
erences
between diabetic and non-diabetic animals were
assessed in a similar manner. The urine glucose
and body weights of animals from both stages of
the study on the days of sacrifice and surgery
were also combined and assessed using a one­
way ANOV A. All results are expressed as the
mean ± the standard error of the mean (SEM).
Vol. 12, No. 6 November/December 2000 
THAWER, ET AL. 
Results 
Diabetes induction. A single tail vein injection 
of alloxan monohydrate into 88 animals resulted 
in a positive urine glucose test in 48 mice yielding 
an induction rate of 54. 5  percent for diabetes 
(Table 1). Body weights were similar in both dia­
betic (n = 48) and non-diabetic animals (n = 40) 
on the day of surgery. Body weights tended to 
decrease in diabetic animals, a finding typical in 
alloxa n-induced experimental DM,31 and 
increased in the non-diabetic animals over the 16-
day experimental period. Non-diabetic animals 
treated with sham ES had significantly (P < 0.01) 
greater body weights compared to diabetic ani­
mals treated with either sham or true ES over the 
time between surgery and sacrifice (Table 1). 
Wound closure: Reliability of measurement of 
wound dimensions . Intrarater reliability, deter­
mined using the ICC11.1), was high using the com­
puter image analysis method of calculating wound 
surface area (0.98), perimeter (0.99), shape factor 
(0.97), and length (0.98). A high degree of agree­
ment was found between measurements of wound 
surface area obtained using the computer image 
analysis and planimetry methods (ICCcz1> = .96). 
Effect of ES: Dose response. Results presented 
in Figure 1 show that ES reduced the surface area, 
perimeter, and length and elevated the shape fac­
tor of wounds in both diabetic and non-diabetic 
animals compared with sham ES. Analysis of the 
effects of ES on diabetic and non-diabetic animals 
within each treatment group revealed decreases in 
the area, perimeter, and length of wounds in both 
diabetic and non-diabetic animals with increasing 
intensities of ES (Figure 1). The perimeter and 
length of wounds in non-diabetic animals treated 
with 10.0V of ES decreased significantly (P < 0.01) 
compared with wounds in sham-treated non-dia­
betic animals (Figure 1). Although the surface area 
of these wounds also tended to decrease, the dif­
ferences were not statistically significant. In dia­
betic animals, a higher voltage of ES (12.SV) was 
required to induce a significant (P < 0.01) change 
in the dimensions of wounds compared to sham­
treated controls. Administration of the highest 
dose of ES (12.SV) to both diabetic and non-dia­
betic animals produced significant change in the 
shape of the wounds (Figure 1 ). This change in the 
165 
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Figure 5. Bors represent the mean± SEM of the surface area measured in a) animals treated with 12.5V of electrical 
current (ES; n = 16) or sham treatment (S; n = 20) for 16 days post surgery; and b) wounds in diabetic animals treated 
with either sham or real ES treatment (D; n = 48) compared to those in non-diabetic animals (ND; n = 40). 
shape factor of the wounds indicated that wounds 
treated with ES were more rounded in shape com­
pared to the linearly shaped wounds of animals 
treated with sham ES (Figure 2). Although not sta­
tistically significant, we found that the mean of 
the diabetic animals treated with lOV of ES did 
not follow the expected decrease but was consis­
tently greater than the mean for sham-treated dia­
betic animals, indicating that diabetic animals 
treated with lOV of ES had larger and more linear­
ly shaped wounds compared with sham-treated 
diabetic animals. 
Effect of ES over time. All wounds, diabetic 
and non-diabetic, increased in surface area 
between surgery and day 2 (Figure 3), a finding 
reported previously, and due to the retraction of 
the margins of the skin.32 Both diabetic and non­
diabetic wounds a dministered ES showed a 
greater increase in wound size on day 2 com­
pared to their sham controls (Figure 3). However, 
wounds in all groups decreased in surface area 
between day 2 and either day 8 or 16 (Figure 3). 
Of the wounds that were treated with 12.SV for 
14 to 16 days (n = 36), those that were non-diabetic 
and treated with ES had markedly higher percent­
age (60%) of closed wounds compared with sham­
treated non-diabetic animals (16.7%) (Figure 4). Dia­
betic wounds treated with ES also had a greater per­
centage of closed wounds (36%) compared with 
sham-treated diabetic animals (12.5%) by day 16 
(Figure 4). As well, diabetic and non-diabetic ani­
mals treated with 12.SV for 16 days (n = 16) had sig­
nificantly (P < 0.01) smaller wound surface area 
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measurements (0.04 ± O.Olmm2) compared with ani­
mals that received sham treatments over the same 
time period (0.08 ± 0.02mm2; n = 20; Figure Sa). 
Effect of diabetes. Al though the measure­
ments of wound dimensions tended to be greater 
in non-diabetic compared to diabetic animals at 
each intensity of ES administered, no statistically 
significant differences were found between dia­
betic and non-diabetic animals (Figure 1). How­
ever, when wound surface area measurements 
made in all diabetic animals (n = 48), regardless 
of the intensity of the electrical stimulus and the 
number of days of treatment, were compared to 
surface area measurements made in non-diabetic 
animals (n = 40), it was found that wound size 
was significantly (P < 0.01) smaller in non-diabet­
ic animals (0.05 ± O.Olmm2) compared with dia­
betic (0.08 ± .03m.m2) animals (Figure Sb). 
Discussion 
ES facilitated wound closure in both diabetic 
and non-diabetic animals. This was reflected by a 
decrease in the dimensions of wounds in both 
diabetic and non-diabetic animals compared with 
sham-treated controls. Although a dose-depen­
dent relationship between ES and wound size 
was not apparent, the highest voltage of ES 
(12.SV) produced the greatest decrease in the 
dimensions of wounds in both diabetic and non­
diabetic animals. Our findings suggest ES may 
have affected the process of wound contraction. 
In the present study, we found that both diabetic 
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and non-diabetic  wounds treated with ES 
appeared more circular in shape. These circular 
wounds also appeared more contracted, resulting 
in the formation of a slightly elevated scar. This 
pattern of wound contraction was most obvious 
in the group that received the highest voltage of 
ES (12.SV). Wound contraction is known to con­
tribute significantly to the closure of excisional 
wounds in loose-skinned animals."·3'1 Further­
more, Weiss, et al.,35 reported a similar observa­
tion following ES treatment using positive polari­
ty of surgically-induced partial-thickness 
wounds. Further studies are needed to examine 
the effects of ES on the myofibroblast and to elu­
cidate the mechanisms underlying the effects of 
ES on wound contraction. 
A full-thickness cutaneous excisional wound 
model was utilized in the present study. This 
model has several advantages over a linear inci­
sional wound model. First, an excisional wound 
model results in an open wound that requires 
considerable fibroplasia to fiJJ the defect. There­
fore, such a model provides more wound tissue 
for the quantification of connective tissue metab­
olism and collagen.36 This is important for subse­
quent studies aimed at elucidating the mecha­
nisms underlying electrically enhanced wound 
closure. An excisional wound also more closely 
resembles the chronic, open wounds encountered 
in clinical situations. Few studies have examined 
the effects of ES on excisional wounds. Assima­
copoulos37 in 1968 and Alvarez, et al.,8 showed 
that low-intensity direct current delivered with a 
negatively active electrode produced an accelera­
tion in the healing of excisional wounds in rabbits 
and domestic pigs, respectively. Both these stud­
ies were performed in young healthy animals. 
AJJoxan monohydrate was used to induce OM 
in healthy, adult male mice. This agent has been 
widely used to induce OM in experimental ani­
mals. The levels of glucosuria measured in our 
study were relatively consistent between diabetic 
animals that received true or sham ES treatment. 
Animals that received an alloxan injection but did 
not exhibit glucosuria were termed non-diabetic 
and served as the control group. These animals 
failed to show glucosuria at the end of the study 
(three weeks post-alloxan injection) and did not 
exhibit symptoms typical of alloxan-induced 
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experimental OM such as polyuria, polydipsia, or 
weight loss. Furthermore, the selective vulner"a­
bility of the insulin-producing islet �-cells com­
pared with other cell types has been attributed to 
a high rate of uptake of alloxan in the �-cells22 and
the high sensitivity of the �-cell toward peroxi­
dases relative to other tissues.23-26 No effects of 
alloxan on other islet cell types have been report­
ed. 38 Studies also indicate that alloxan does not 
appear to irreversibly affect lymphoid function 
and the functions critical to the generation of an 
immune response,25 nor does it affect collagenase 
activity.24 Therefore, it is unlikely that animals in 
the present study that were termed non-diabetic 
could have been diabetic without detectible urine 
glucose. Animals identified as having glucose in 
the urine were termed diabetic. These animals 
also exhibited typical symptoms of alloxan­
induced experimental OM such polyuria, poly­
dipsia, and weight loss by five days following 
alloxan injection. Alloxan produced OM in 54.5 
percent of animals injected. This relatively low 
diabetic induction rate is probably reflective of 
the technical difficulty of performing tail vein 
injections in such a small animal species. 
Smith, et al.,13 reported pathologic changes in
the epidermis and scar of mice following five 
days of alloxan injection and a subsequent two 
weeks of treatment with ES. Therefore, although 
the three-week period may not be long enough to 
generate complications of OM such as atheroscle­
rosis, neuropathy, and retinopathy, it is sufficient 
to produce cutaneous changes characteristic of 
OM. Using this alloxan-induced diabetic model, 
we have also reported that lower amounts of col­
lagen were recorded in the superficial and deep 
scar of wounded and adjacent unwounded tis­
sues in diabetic animals compared with non-dia­
betic animals.39.<0 This result is in agreement with 
earlier reports that also document a decrease in 
the repair of deeper wounds that require collagen 
formation in diabetic animals.41
Computer image analysis was used to docu­
ment the dimensions of wounds. This method 
uses pixel counting to calculate wound dimen­
sions. This study showed that the computer 
image analysis and planimetry methods provided 
measurements of wound dimensions that demon­
strated equivalent accuracy and intrarater relia-
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bility. The planimetry method has previously 
been shown to have an intrarater and interrater 
reliability of 0.99.28•29•42 The planimetry method is 
considered to be the gold standard for the docu­
mentation of wound dimensions.42,4.1 This comput­
er analysis method may be used to accurately and 
reliably document change in wound dimensions. 
Using reliable and valid computerized image 
analysis techniques, we have demonstrated that 
ES significantly reduced the dimensions of 
wounds, and significantly altered the shape of 
wounds in both non-diabetic and diabetic mice. 
Further studies are needed to examine the mecha­
nisms underlying this electrically induced wound 
closure and change in shape seen in diabetic ani­
mals. 
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